This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A New Understanding

Sanford H. Roth, MD

Arch Intern Med. 1996;156(15):1623-1628.

Abstract
Nonsteroidal anti-inflammatory drug (NSAID) gastropathy is associated with substantial morbidity and mortality, which result in high costs to both the patient and society. The subset of patients who are at greatest risk for developing NSAID gastropathy continues to be better defined, but various risk factors, such as age and previous gastrointestinal tract disease, have been identified. In patients receiving older NSAIDs, the choice of NSAID should be based on differences in formulations at the lowest effective dose. Gastroprotective cotherapy should be instituted if treatment with older NSAIDs is continued in at-risk patients; misoprostol is currently the only agent approved for this indication. The impact of misoprostol on clinical gastrointestinal tract end points has recently been documented. Newer NSAIDs may have an improved safety profile over older NSAIDs; some have a clinically documented reduction in the incidence of adverse gastrointestinal tract effects. An understanding of these issues should enable the informed clinician to choose an NSAID on the basis of risk-benefit and costbenefit considerations.

Arch Intern Med. 1996;156:1623-1628

Author Affiliations
From the Arthritis Center Ltd, Phoenix, Ariz.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Decreasing incidence of symptomatic gastrointestinal ulcers and ulcer complications in patients with rheumatoid arthritis
Steen et al.
Ann Rheum Dis 2008;67:256-259.
ABSTRACT | FULL TEXT  

A Comparison of Educational Methods to Improve NSAID Knowledge and Use of a Medication List in an Elderly Population
Gates et al.
Home Health Care Management Practice 2005;17:403-410.
ABSTRACT  

Efficacy and Safety of a Topical Diclofenac Solution (Pennsaid) in the Treatment of Primary Osteoarthritis of the Knee: A Randomized, Double-Blind, Vehicle-Controlled Clinical Trial
Roth and Shainhouse
Arch Intern Med 2004;164:2017-2023.
ABSTRACT | FULL TEXT  

Pathophysiology of vascular dysfunction in a rat model of chronic joint inflammation
Egan et al.
J. Physiol. 2004;557:635-643.
ABSTRACT | FULL TEXT  

Association Between Naproxen Use and Protection Against Acute Myocardial Infarction
Rahme et al.
Arch Intern Med 2002;162:1111-1115.
ABSTRACT | FULL TEXT  

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Research to Help Your Patients Use them Safely
Setter et al.
Home Health Care Management Practice 2001;13:468-475.
ABSTRACT  

Arthritis therapy: a better time, a better day
Roth
Rheumatology (Oxford) 2001;40:603-606.
FULL TEXT  

Incidence of clinically manifest ulcers and their complications in patients with rheumatoid arthritis
Steen et al.
Ann Rheum Dis 2001;60:443-447.
ABSTRACT | FULL TEXT  

Around-the-Clock, Controlled-Release Oxycodone Therapy for Osteoarthritis-Related Pain: Placebo-Controlled Trial and Long-term Evaluation
Roth et al.
Arch Intern Med 2000;160:853-860.
ABSTRACT | FULL TEXT  

Cyclooxygenase in biology and disease
Dubois et al.
FASEB J. 1998;12:1063-1073.
ABSTRACT | FULL TEXT  

Intestinal perforation in a patient with severe ankylosing spondylitis
Leitch and Fordham
Ann Rheum Dis 1997;56:458-460.
FULL TEXT